VCAR33-CLL1

**VCAR33-CLL1** is an investigational donor-derived allogeneic **CAR-T cell therapy** developed by **Vor Biopharma** for myeloid malignancies, particularly relapsed or refractory **acute myeloid leukemia** and **myelodysplastic syndrome** after allogeneic hematopoietic cell transplantation. Based on the provided context, it appears to be a **CLL1-targeting variant or specific construct within the VCAR33 program**, distinct from the CD33-directed VCAR33 product described in the excerpt. As a CAR-T therapy, its intended mechanism is to engineer donor-derived T cells to recognize a leukemia-associated surface antigen and mediate cytotoxic elimination of malignant cells. The exact construct details, binding domain design, co-stimulatory domains, manufacturing process specifics, and clinical status for the exact name **VCAR33-CLL1** were not explicitly provided in the supplied text, so those attributes should be interpreted cautiously.